Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts

Milestone Pharmaceuticals Inc.

2026-Q1 EPS reported -$0.20 revenue$238,000

Product revenue of $0.2M from first quarter of CARDAMYST launch; no prior-year revenue.
Net loss $26.1M ($0.20 per share) vs $20.8M ($0.31) a year ago; cash $184.2M, runway into H2 2027.
~600 scripts filled for 560 PSVT patients; ~400 unique prescribers as of April.
Express Scripts national formulary coverage effective March 27, 2026; >25% of commercially insured lives covered.
Phase 3 AFib-RVR trial initiated; first patient enrollment expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Milestone Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $0.2 million.

Period: the first quarter ended March 31, 2026
Revenue: $0.2 million
Result: reported results

Exact text from the filing

into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above. · Product revenues were $0.2 million during the three months ended March 31, 2026. There was no product revenue during the three months ended March 31, 2025. · Research and development expense for the first

View on SEC.gov

709 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.